Physician profile

Jane M Becht

Acute Care (Nurse Practitioner) · Buffalo, NY

NPI 1629283163

$618.38

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$359.05

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $428.93 2021-2023 Lifevest
Atricure, INC. $53.21 2021
Edwards Lifesciences Corporation $41.50 2022-2023 Inspiris Resilia Aortic Valve
Smith+Nephew, INC. $33.85 2022-2023 Pico, Renasys Touch
Kci USA, INC. $24.63 2023 V.A.C. Veraflo, Prevena
Kestra Medical Technology Services, INC. $18.71 2022
Chiesi USA, INC. $17.55 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jane M Becht

$618.38

in general payments reported 2019-2025

Years
2021-2023
Top company
Zoll Services LLC (A/K/A Zoll Lifecor Corp)

https://glasscript.com/doctor/10474279/jane-m-becht

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.